Otolaryngology · Houston, TX
NPI
1386635415
Since 2005
Specialty
Otolaryngology
Code 207Y00000X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
7737 Southwest Fwy
Houston, TX, 77074
Phone (713) 774-2090
Groups this clinician bills Medicare through
Medicare paid, 2024
$29K
1,210 services
Medicare patients, 2024
85
Average age 69
Drug cost, 2024
$143K
3,298 prescriptions
Company payments, 2025
$803
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jay Chavda was code 95165 (treatment - miscellaneous), 350 times for 11 patients. In total Jay Chavda billed 1,210 services in 34 codes, and Medicare paid $29K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-07-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95165 Treatment - Miscellaneous | Office | 350 | 11 | $11.06 | $3,871 |
| 99214 Office E&M - Established | Office | 127 | 57 | $87.89 | $11K |
| 97112 PT Treatment | Office | 125 | 11 | $22.12 | $2,766 |
| 99204 Office E&M - New | Office | 34 | 34 | $96.99 | $3,298 |
| 92557 Vision, Hearing, and Speech Services | Office | 19 | 18 | $25.02 | $475 |
| 92588 Test - Miscellaneous | Office | 19 | 18 | $23.34 | $444 |
| 92550 Test - Miscellaneous | Office | 19 | 18 | $15.30 | $291 |
By year: 2022 $46K for 2,099 services; 2023 $69K for 2,035 services; 2024 $29K for 1,210 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jay Chavda prescribed most often to Medicare patients was Montelukast Sodium, with 674 prescriptions and refills. In total Jay Chavda wrote 3,298 Medicare prescriptions that cost $143K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Montelukast Sodium Generic | 674 | 1,339 | 271 | $4,728 |
| Omeprazole Generic | 521 | 1,025 | 221 | $7,041 |
| Fluticasone Propionate Generic | 398 | 620 | 178 | $6,153 |
| Meloxicam Generic | 365 | 571 | 165 | $1,167 |
| Neomycin-Polymyxin-Hc Neomycin/Polymyxin B/Hydrocort | 253 | 318 | 120 | $13K |
| Levocetirizine Dihydrochloride Generic | 141 | 280 | 56 | $1,612 |
| Diclofenac Sodium Generic | 107 | 138 | 58 | $2,163 |
| Xhance Fluticasone Propionate | 90 | 100 | 36 | $66K |
| Mupirocin Generic | 80 | 84 | 49 | $559 |
| Metoclopramide Hcl Generic | 65 | 78 | 23 | $343 |
| Amoxicillin Generic | 56 | 56 | 55 | $210 |
| Cephalexin Generic | 54 | 54 | 48 | $794 |
| Neomycin-Polymyxin-Hydrocort Neomycin/Polymyxin B/Hydrocort | 46 | 47 | 17 | $1,582 |
| Ipratropium Bromide Generic | 45 | 73 | 27 | $1,013 |
| Meclizine Hcl Generic | 41 | 77 | 20 | $416 |
Brand drugs: - claims; generic drugs: 3,099 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jay Chavda $803 ($803 in general payments such as food, travel and fees) from 11 companies. The largest payer was Takeda Pharmaceuticals U.S.A., Inc. with $246.
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 6 | $246 |
| GlaxoSmithKline, LLC. GSK | 2 | $152 |
| Optinose US, Inc. | 4 | $103 |
| Grifols USA, LLC | 1 | $93.86 |
| ARS Pharmaceuticals Operations, Inc. SPRY | 1 | $48.81 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $39.27 |
| Vertex Pharmaceuticals Incorporated VRTX | 1 | $29.01 |
| Paratek Pharmaceuticals, Inc. | 1 | $26.46 |
| Jubilant HollisterStier LLC | 1 | $24.7 |
| Carl Zeiss Meditec USA, Inc. | 1 | $21 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.